Intervention

hepatic arterial infusion chemotherapy (HAIC)

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting2

Common conditions5

Lead sponsors shown3

Clinical trials

4 shown

Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialNCT07847710 · 2026-08-01

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)NCT06859684 · 2025-03-01

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaNCT07353827 · 2026-02-01

NOT_YET_RECRUITING

HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICCNCT07304388 · 2023-02-10

Common conditions

Intrahepatic Cholangiocarcinoma (Icc)4 Durvalumab1 HAIC1 Hepatic Arterial Infusion Chemotherapy1 Neoadjuvant Therapy1

Leading sponsors

Sun Yat-sen University2 The First Affiliated Hospital with Nanjing Medical University1 West China Hospital1

Trial status mix

RECRUITING2

COMPLETED1

NOT_YET_RECRUITING1

Phase mix

PHASE24

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.